Atomoxetine and risk of Alzheimer's disease in older adults
Аннотация
Abstract INTRODUCTION Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's disease (AD). Its association with incident AD is unclear. METHODS This non‐concurrent prospective study emulated a target trial among Medicare beneficiaries (January 1, 2007–December 31, 2023). The primary outcome was AD, determined using a validated algorithm. We estimated 5‐ and 10‐year risk ratios (RRs) and risk differences (RDs). Analyses were examined overall and by indication. RESULTS This study included 70,367 person‐trials (74.6% ≥70 years; 59.5% female; 86.7% non‐Hispanic White). Initiation of atomoxetine versus no initiation was not associated with 5‐ or 10‐year risk of AD but was associated with lower risk of AD‐free death. In indication‐specific analyses, atomoxetine was associated with lower 5‐year risk of AD and AD‐free death among individuals with depression. DISCUSSION Initiation of atomoxetine was not associated with lower risk of AD later in life. The lower risk of AD among people with depression warrants further study.